Serum CRP in patients with gout and effects of benzbromarone

Okuda, Chihiro; Koyama, Hidenori; Tsutsumi, Zenta; Yamamoto, Asami; Kurajoh, Masafumi; Moriwaki, Yuji; Yamamoto, Tetsuya

doi:10.5414/cp201425

Cited by 16 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although hyperuricemia is known to predict development of hypertension 26,28 and XOR inhibitor administration has been reported to lower BP 7,8 , many [29][30][31][32] , though not all 33 studies have found no effect from administration of uricosuric agents such as benzbromarone on BP. Furthermore, administration of the urate precursor inosine was reported to not to raise BP in subjects with Parkinson's disease 34 or multiple sclerosis 35 .…”

Section: Or (95% Ci) Pmentioning

confidence: 99%

Association of plasma xanthine oxidoreductase activity with blood pressure affected by oxidative stress level: MedCity21 health examination registry

Yoshida

Kurajoh

Fukumoto

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Xanthine oxidoreductase (XoR) inhibitor administration reduces uric acid and reactive oxygen species (RoS) production, and also lowers blood pressure (Bp). However, the associations of plasma XoR activity, uric acid level, and oxidative stress levels with Bp remain unclear. this cross-sectional study included 156 subjects (68 males, 88 females) registered in the MedCity21 health examination registry without anti-hypertensive or anti-hyperuricemic agent administration. plasma XoR activity was measured using our highly sensitive novel assay, which is unaffected by uric acid in the sample. Bp was also determined, and serum uric acid and derivative of reactive oxygen metabolites (d-RoMs) levels were simultaneously measured. Median plasma XoR activity, serum uric acid, d-RoMs, and mean arterial pressure (MAP) values were 25.7 pmol/h/mL, 5.4 mg/dL, 305 Carr U, and 89.0 mmHg, respectively. Multiple regression analysis showed that plasma XoR activity (β = 0.211, p = 0.019), but not serum uric acid (β = 0.072, p = 0.502), was significantly associated with MAP. In subjects with lower but not higher d-RoMs level, an independent association of plasma XoR activity with MAp was observed (β = 0.428, p = 0.001 and β = 0.019, p = 0.891, respectively; p for interaction = 0.046). XoR may contribute to the pathophysiology of higher Bp through RoS but not uric acid production, especially in patients with lower oxidative stress.

show abstract

Section: Or (95% Ci) Pmentioning

confidence: 99%

Association of plasma xanthine oxidoreductase activity with blood pressure affected by oxidative stress level: MedCity21 health examination registry

Yoshida

Kurajoh

Fukumoto

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…28) Further research is needed to determine the possible utility of allopurinol and benzbromarone in the treatment of cardiac disease.…”

Section: )mentioning

confidence: 99%

Is Hyperuricemia a Risk Factor for Arteriosclerosis? Uric Acid and Arteriosclerosis in Apolipoprotein E-Deficient Mice

Wakuda

Uchida

Ikeda

et al. 2014

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Although hyperlipidemia, high blood pressure, and diabetes increase the risk of arteriosclerosis, it is not clear whether hyperuricemia increases the risk of arteriosclerosis or not. We examined the effects of uric acid and curative drugs for hyperuricemia on atherosclerosis-susceptible C57BL/6J apolipoprotein E-deficient (apoE / ) mice. Male apoE / mice (age: 6 weeks) were fed a normal diet (normal diet group) or a uric acid-enriched diet. Mice fed the uric acid-enriched diet were divided into three groups and administered a drinking vehicle (high uric acid diet group), allopurinol (20 mg·kg 1 ·d 1 ), or benzbromarone (20 mg·kg 1 ·d 1 ) for 10 weeks. Serum uric acid concentrations were higher in the high uric acid diet group than in the normal diet group, and concentrations in the allopurinol and benzbromarone groups were lower than in the high uric acid diet group. Serum total cholesterol and triglyceride levels were lower in the allopurinol group than in the high uric acid diet group. Oxidative stress was lower in the benzbromarone group than in the high uric acid diet group. Atherosclerotic lesion areas were smaller in the allopurinol and benzbromarone groups than in the high uric acid diet group. Thus, hyperuricemia may not be an independent risk factor for arteriosclerosis; however, the administration of allopurinol and benzbromarone prevented the development of atherosclerosis in apoE / mice fed a uric acid-enriched diet. The anti-atherosclerotic effect was in part due to lower total cholesterol and oxidative stress in the serum. Other possible mechanisms underlying this effect should be investigated.

show abstract

“…SERPINE1, one of the serine protease inhibitors, played a pathophysiological role in the synovial fluid of gouty arthritis [24]. CRP, an acute reactant protein, had a primitive defense function against the exogenous stimulus, which was significant part of inflammation [25]. COX2 was encoded by the PTGS2 gene, which participated in pathological processes such as inflammation and fever [26].…”

Section: Ppi Networkmentioning

confidence: 99%

Study on the Multitarget Mechanism of Sanmiao Pill on Gouty Arthritis Based on Network Pharmacology

Qian

Jin

Liu

et al. 2020

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Sanmiao pill (SMP), a Chinese traditional formula, had been used to treat gouty arthritis (GA). However, the active compounds and underlying mechanism remained unclear. Hence, network pharmacology and molecular docking were utilized to explore bioactive compounds and potential mechanism of action of SMP in treating GA. In the study, the compounds of SMP, corresponding targets, and GA-related targets were mined from various pharmacological databases. Then, herb-compound-target, compound-target, PPI, and target-pathway networks were constructed. Ultimately, molecular docking was carried out to verify the predicted results. The results indicated that 47 active compounds, 338 targets, and 144 disease targets were collected. Network analysis implied that Phellodendron chinense Schneid. played a vital role in the whole formula. Moreover, 7 compounds (quercetin, kaempferol, wogonin, rutaecarpine, baicalein, beta-sitosterol, and stigmasterol) and 4 targets (NFKB1, RELA, MAPK1, and TNF) might be the kernel compounds and targets of SMP against GA. According to GOBP and KEGG pathway enrichment analysis and target-pathway network, SMP might exert a therapeutic role in GA by regulating numerous biological processes and pathways, including lipopolysaccharide-mediated signaling pathway, positive regulation of transcription, Toll-like receptor signaling pathway, JAK-STAT signaling pathway, NOD-like receptor signaling pathway, and MAPK signaling pathway. The results of molecular docking showcased that 11 pairs of compound with targets had tight binding strength. Thereinto, 4 compounds of MAPK1 and 5 compounds of NFKB1 possessed a better combination, suggesting that MAPK1 and NFKB1 might be considered as therapeutic targets in treatment of GA. This study verified that SMP had synergistic effect on GA by multicomponents, multitargets, and multipathways.

show abstract

Serum CRP in patients with gout and effects of benzbromarone

Cited by 16 publications

References 0 publications

Association of plasma xanthine oxidoreductase activity with blood pressure affected by oxidative stress level: MedCity21 health examination registry

Association of plasma xanthine oxidoreductase activity with blood pressure affected by oxidative stress level: MedCity21 health examination registry

Is Hyperuricemia a Risk Factor for Arteriosclerosis? Uric Acid and Arteriosclerosis in Apolipoprotein E-Deficient Mice

Study on the Multitarget Mechanism of Sanmiao Pill on Gouty Arthritis Based on Network Pharmacology

Contact Info

Product

Resources

About